| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJI.201242799 |
| P698 | PubMed publication ID | 23303646 |
| P50 | author | Sharon R. Lewin | Q37618308 |
| Jose A. Villadangos | Q38360717 | ||
| Justine D. Mintern | Q39631810 | ||
| Irina Caminschi | Q41610434 | ||
| Elodie Segura | Q56433247 | ||
| Gabriela Khoury | Q63682046 | ||
| Paul Urquhart Cameron | Q67957474 | ||
| P2093 | author name string | Jessica M Moffat | |
| P2860 | cites work | Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction | Q24309134 |
| BST-2/tetherin: a new component of the innate immune response to enveloped viruses | Q24630382 | ||
| Structural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus Release | Q27665937 | ||
| Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors | Q28585599 | ||
| Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu | Q29547836 | ||
| Differential antigen processing by dendritic cell subsets in vivo | Q29615177 | ||
| Mature dendritic cells use endocytic receptors to capture and present antigens | Q30493720 | ||
| Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells | Q33862227 | ||
| CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. | Q33928441 | ||
| Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody | Q34310888 | ||
| The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture | Q34771172 | ||
| In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans | Q35170879 | ||
| Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo | Q35518677 | ||
| Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. | Q35784640 | ||
| Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling | Q35826825 | ||
| The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement | Q36941087 | ||
| HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase | Q37262510 | ||
| Antigen-presentation properties of plasmacytoid dendritic cells | Q37272231 | ||
| Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors | Q39757211 | ||
| Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models | Q39912541 | ||
| Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma | Q40394699 | ||
| Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes | Q41578289 | ||
| Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection | Q42091648 | ||
| Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells | Q42767669 | ||
| Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. | Q43620870 | ||
| Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. | Q44664018 | ||
| Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity | Q45264704 | ||
| Enhancing immune responses by targeting antigen to DC. | Q46104542 | ||
| CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. | Q51971372 | ||
| The C-Type Lectin Clec12A Present on Mouse and Human Dendritic Cells Can Serve as a Target for Antigen Delivery and Enhancement of Antibody Responses | Q57133306 | ||
| Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells | Q57134111 | ||
| Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection | Q57227959 | ||
| Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements | Q57228054 | ||
| Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation | Q57275870 | ||
| Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs | Q57920497 | ||
| Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype | Q77519513 | ||
| HIV induces maturation of monocyte-derived dendritic cells and Langerhans cells | Q79326773 | ||
| Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity | Q82486810 | ||
| Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity | Q84069177 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone marrow | Q546523 |
| P304 | page(s) | 595-605 | |
| P577 | publication date | 2013-02-06 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation | |
| P478 | volume | 43 |
| Q60956640 | Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? |
| Q56895711 | BST-2 controls T cell proliferation and exhaustion by shaping the early distribution of a persistent viral infection |
| Q37524465 | Controlling immune responses by targeting antigens to dendritic cell subsets and B cells |
| Q42696952 | Dendritic cell-targeted vaccines--hope or hype? |
| Q35852742 | Differential use of autophagy by primary dendritic cells specialized in cross-presentation |
| Q35840924 | Endogenous Murine BST-2/Tetherin Is Not a Major Restriction Factor of Influenza A Virus Infection |
| Q24297949 | Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1 |
| Q26746162 | Targeting dendritic cells: a promising strategy to improve vaccine effectiveness |
| Q38235001 | Targeting human dendritic cells in situ to improve vaccines. |
| Q91999288 | The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells |
| Q33840201 | The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. |
Search more.